P41252 AF NFT

Isoleucine--tRNA ligase, cytoplasmic

MOLNFT AF v1 smart contract in GenesisL1 blockchain: 
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
IPFS of NFT metadata: 
bafybeiehtjlac7rwt6nrn7rp2vaqj4dfbzoglvfv564b2ij3yto5xaeksy/metadata.json
IPFS of structure file: 
bafybeigttsukwt3jzprzghzgajhtx5e6lx37bw7ixbar5trnqgtgi7kvaq/AF-P41252-F1-model_v2.pdb
First NFT owner address (eip-55): 
0x362a6d063b1B7E1B6EfD3A9A7CA3612e3FE037AA
First NFT owner address (bech32): 
genesis1xc4x6p3mrdlpkmha82d8egmp9cl7qda2uxz2xy
Current NFT ID #448711 owner (web3):

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1

NFT id:
448711
Accession (UniProt):
P41252
Name::
Isoleucine--tRNA ligase, cytoplasmic
Experimental Method:
Predicted structure
Sequence source:
HOMO SAPIENS

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT P41252 research and analysis (ICN3D with VR)

FASTA sequences

>sp|P41252|SYIC_HUMAN Isoleucine--tRNA ligase, cytoplasmic OS=Homo sapiens OX=9606 GN=IARS1 PE=1 SV=2 MLQQVPENINFPAEEEKILEFWTEFNCFQECLKQSKHKPKFTFYDGPPFATGLPHYGHILAGTIKDIVTRYAHQSGFHVDRRFGWDCHGLPVEYEIDKTLGIRGPEDVAKMGITEYNNQCRAIVMRYSAEWKSTVSRLGRWIDFDNDYKTLYPQFMESVWWVFKQLYDKGLVYRGVKVMPFSTACNTPLSNFESHQNYKDVQDPSVFVTFPLEEDETVSLVAWTTTPWTLPSNLAVCVNPEMQYVKIKDVARGRLLILMEARLSALYKLESDYEILERFPGAYLKGKKYRPLFDYFLKCKENGAFTVLVDNYVKEEEGTGVVHQAPYFGAEDYRVCMDFNIIRKDSLPVCPVDASGCFTTEVTDFAGQYVKDADKSIIRTLKEQGRLLVATTFTHSYPFCWRSDTPLIYKAVPSWFVRVENMVDQLLRNNDLCYWVPELVREKRFGNWLKDARDWTISRNRYWGTPIPLWVSDDFEEVVCIGSVAELEELSGAKISDLHRESVDHLTIPSRCGKGSLHRISEVFDCWFESGSMPYAQVHYPFENKREFEDAFPADFIAEGIDQTRGWFYTLLVLATALFGQPPFKNVIVNGLVLASDGQKMSKRKKNYPDPVSIIQKYGADALRLYLINSPVVRAENLRFKEEGVRDVLKDVLLPWYNAYRFLIQNVLRLQKEEEIEFLYNENTVRESPNITDRWILSFMQSLIGFFETEMAAYRLYTVVPRLVKFVDILTNWYVRMNRRRLKGENGMEDCVMALETLFSVLLSLCRLMAPYTPFLTELMYQNLKVLIDPVSVQDKDTLSIHYLMLPRVREELIDKKTESAVSQMQSVIELGRVIRDRKTIPIKYPLKEIVVIHQDPEALKDIKSLEKYIIEELNVRKVTLSTDKNKYGIRLRAEPDHMVLGKRLKGAFKAVMTSIKQLSSEELEQFQKTGTIVVEGHELHDEDIRLMYTFDQATGGTAQFEAHSDAQALVLLDVTPDQSMVDEGMAREVINRIQKLRKKCNLVPTDEITVYYKAKSEGTYLNSVIESHTEFIFTTIKAPLKPYPVSPSDKVLIQEKTQLKGSELEITLTRGSSLPGPACAYVNLNICANGSEQGGVLLLENPKGDNRLDLLKLKSVVTSIFGVKNTELAVFHDETEIQNQTDLLSLSGKTLCVTAGSAPSLINSSSTLLCQYINLQLLNAKPQECLMGTVGTLLLENPLGQNGLTHQGLLYEAAKVFGLRSRKLKLFLNETQTQEITEDIPVKTLNMKTVYVSVLPTTADF